<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471470</url>
  </required_header>
  <id_info>
    <org_study_id>AMC ONCGI-1003</org_study_id>
    <nct_id>NCT01471470</nct_id>
  </id_info>
  <brief_title>Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer</brief_title>
  <official_title>A Phase II Study of Neoadjuvant Chemotherapy With Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether docetaxel, capecitabine, cisplatin, and
      bevacizumab are effective in the treatment of unresectable advanced gastric cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In our previous phase II study of neoadjuvant docetaxel, capecitabine and cisplatin
      chemotherapy, patients with unresectable gastric cancer because of invasion to adjacent
      organs or metastasis to para-aortic lymph nodes received benefit from neoadjuvant
      chemotherapy. Based on these results and reports that bevacizumab enhances response rate, we
      planned docetaxel, capecitabine, cisplatin, and bevacizumab as neoadjuvant chemotherapy for
      patients with local invasion or para-aortic node metastasis alone.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2010</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>Up to 4 weeks after surgery</time_frame>
    <description>R0 resection means complete resection of tumor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Overall survival will be measured from the start of study treatment to documented death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenetic biomarkers</measure>
    <time_frame>Baseline and 6 weeks after treatment</time_frame>
    <description>cluster of differentiation 31, microvessel density, platelet derived growth factor, vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1, vascular endothelial growth factor receptor-2, Neuropilin 1 and phosphatidylinositol glycan anchor biosynthesis, class F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time to progression will be measured from the start of study treatment to documented tumor progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Treatment toxicities are evaluated according to the NCI common toxicity criteria version 3.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>neoadjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, Capecitabine, Cisplatin, Bevacizumab</intervention_name>
    <description>Bevacizumab 7.5mg/kg IV (D1) Docetaxel 60 mg/m2 IV (D1) Cisplatin 60 mg/m2 IV (D1) Xeloda 1,875 mg/m2/day/bid PO (D1-D14)</description>
    <arm_group_label>neoadjuvant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented adenocarcinoma of the stomach or gastroesophageal junction.

          -  Invasion to adjacent organ (T4) proven by endoscopic ultrasonography (EUS) or presence
             of paraaortic lymph node metastasis by CT and PET(short-axis diameter &gt; 1 cm showing
             hot uptake in PET scan).

          -  Age 18-70 years old

          -  ECOG performance status 0-2

          -  Adequate hepatic function(serum bilirubin &lt;1.5mg/dl, AST (SGOT) and ALT (SGPT) &lt; 2.5 x
             UNL, alkaline phosphatase &lt; 5 x UNL)

          -  Adequate renal function(serum creatinine &lt;1.5mg/dl)

          -  Adequate bone marrow function (WBC ≥4000 cell/㎕ with ANC ≥1500 cell/㎕, platelet count
             ≥100,000 cell/㎕)

          -  HER2 negative (HER2 immunohistochemistry 0 or 1+, immunohistochemistry 2+ but FISH
             negative)

          -  Informed consent

        Exclusion Criteria:

          -  Other histologic type than adenocarcinoma

          -  Metastasis in other sites than paraaortic lymph nodes, like in liver or peritoneum.

          -  Presence or history of other cancers

          -  History of prior chemotherapy, antiangiogenic agents, or radiation.

          -  Patients with definite ascites in abdomen CT scan

          -  Presence of not adequately controlled CNS metastasis

          -  Bowel obstruction

          -  Evidence of gastrointestinal bleeding

          -  Other serious illness or medical conditions including hypertension uncontrolled by
             medication.

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Koo Kang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2011</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Yoon-Koo Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Advanced gastric cancer</keyword>
  <keyword>Neoadjuvant</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

